Remus' Stepdown Subsidiary Faces Penalty from US Tax Authority Over Alleged Non-Payment
Remus Pharmaceuticals Limited has reported that its stepdown subsidiary, Espee Biopharma & Finechem LLC (EBFL), has received a penalty notice from the Department of the Treasury Internal Revenue Service (IRS) regarding alleged tax deficiencies. The penalty, amounting to USD 14,247.38, stems from allegations of non-payment and late filing of taxes by EBFL to the IRS.The notice was issued by the IRS, and Remus Pharmaceuticals Limited confirmed that the communication was received on June 19, 2026.
EBFL has responded to the imposition of the penalty. The company states that it believes no case for penalization exists since the necessary tax amount had already been paid. Furthermore, EBFL is actively engaging with the IRS to secure necessary clarifications and corrections regarding the matter.
A review of the situation highlights the key details concerning the action taken by the authority.
| Detail | Information |
|---|---|
| Name of Authority | Department of the Treasury Internal Revenue Service (IRS) |
| Nature of Action | Penalty imposed on EBFL over alleged tax non-payment |
| Date of Notice Receipt | June 19, 2026 |
| Penalty Amount | USD 14,247.38 |
| Violation Allegation | Non-payment and late filing of tax by EBFL to IRS |
Regarding the impact on the company's operations, Remus Pharmaceuticals Limited stated that there is no material impact on its financial standing or operational activities resulting from this notice received by EBFL.
REMUS Stock Price Movement
Shares of Remus Pharmaceuticals Limited slipped by 3.32% on Friday, settling at ₹799.95. The stock recorded a trading volume of 3,200 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.